Loading data for LIMN — first visit, this takes a few seconds.
Liminatus Pharma, Inc. (LIMN)
NasdaqCM: LIMN
· Real-Time Price · USD
3.58
-0.28 (-7.25%)
At close: Aug 31, 2026, 8:00 PM
3.80
-1.55%
Pre-market: 5:10 AM
The price, the headline numbers and the latest news, in one place.
Liminatus Pharma, Inc. (LIMN) Stock Price, Analysis & Data
No data available
| Bid | 3.02 |
| Market Cap | 5.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.5M |
| 0.74 | |
| -21.9 | |
| n/a | |
| n/a | |
| P/B (ttm) | -1286.67 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 4.22 |
| Volume | 43,646 |
| Avg. Volume (20D) | 691,233 |
| Open | 3.80 |
| Previous Close | 3.86 |
| Day's Range | 3.48 - 3.80 |
| 52-Week Range | 3.48 - 154.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LIMN
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California....
Industry Biotechnology
Sector Healthcare
IPO Date May 2, 2025
Employees 1
Stock Exchange NasdaqCM
Ticker Symbol LIMN
Website https://liminatuspharma.com
Financial Performance
In 2025, Liminatus Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.21M, an increase of 187.81%.
Financial StatementsEarnings Surprise
Liminatus Pharma has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
6 months ago · Associated Press Finance
BC-Most Active StocksPagaya Technologies Ltd. 23,855,890 15.29